Angeion Corporation Introduces the Medical Graphics Platinum Elite(TM) Series Plethysmograph for Pulmonary Function Testing.

SAINT PAUL, Minn. -- Angeion Corporation (NASDAQ: ANGN) today introduced the Medical Graphics Platinum Elite[TM] Series plethysmograph. Based on the award winning Elite Series design, the Platinum Elite offers advanced functionality, ease of operation, precision, reliability and improved patient comfort. Designed for use in hospitals and doctors' offices, the Platinum Elite is used to measure pulmonary function in the diagnosis of airway diseases such as chronic obstructive pulmonary disease (COPD), asthma, emphysema, allergies and other lung conditions.

The Platinum Elite incorporates several new features to improve diagnostic and on-going disease management capability. The system can test pediatric through adult patients and the expanded seating space accommodates larger and tall patients with virtually no weight restriction. The system's advanced sensor technology is self-monitoring, self diagnostic and auto-adjusting to simplify system operation. New digital technology affords the maximum in accuracy, reliability, speed and serviceability.

"In diagnosing COPD, asthma and other conditions affecting lung function, the Platinum Elite provides solutions for the most challenging clinician and patient needs," said Rod Young, Angeion President and Chief Executive Officer. "The Platinum Elite simplifies the diagnostic process by eliminating the need for the operator to monitor and adjust controls, allowing full attention on the patient. Plethysmography is the gold standard for measuring pulmonary function and offers many clinical benefits compared to simple spirometry for the diagnosis and management of these conditions. The Platinum Elite is the most advanced plethysmograph available today."

According to WebMD, COPD is the fourth leading cause of death in the United Sates, affecting approximately 32 million adults. It is also the fifth leading cause of death worldwide. The new Platinum Elite offers physicians the ability to diagnose and treat these patients quickly, with a system that is cost effective to operate and ideally suited to the physician office environment.

Platinum Elite incorporates new BREEZESUITE[TM] software developed specifically for ease of use in this state of the art pulmonary diagnostic device. This proprietary software can be integrated with other Medical Graphic's cardio respiratory diagnostic equipment, providing an additional advantage for the clinician and the operator.

The Platinum Elite Series is available in three different models, providing combinations of different testing functionality. The Series is available for immediate shipment.

About Angeion Corporation

Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardio respiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand and trade names. These cardio respiratory diagnostic systems have a wide range of applications in healthcare as well as health and fitness. The Company's products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians' offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.

The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements by their nature involve substantial risks and uncertainties. Our actual results may differ materially depending on a variety of factors including: (i) our ability to successfully operate our business including our ability to develop, improve, and update our cardio respiratory diagnostic products and successfully sell these products into existing and new markets, (ii) our ability to achieve constant margins for products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers, (iii) our ability to effectively manufacture and ship products in required quantities to meet customer demands, (iv) our ability to successfully defend ourselves from product liability claims related to our cardio respiratory diagnostic products and claims associated with our prior cardiac stimulation products, (v) our ability to protect our intellectual property, (vi) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures, and (vii) our dependence on third-party vendors.

Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2007.